[go: up one dir, main page]

MX2009006475A - Composiciones de diclorhidrato de azimilida. - Google Patents

Composiciones de diclorhidrato de azimilida.

Info

Publication number
MX2009006475A
MX2009006475A MX2009006475A MX2009006475A MX2009006475A MX 2009006475 A MX2009006475 A MX 2009006475A MX 2009006475 A MX2009006475 A MX 2009006475A MX 2009006475 A MX2009006475 A MX 2009006475A MX 2009006475 A MX2009006475 A MX 2009006475A
Authority
MX
Mexico
Prior art keywords
compositions
azimilide dihydrochloride
dihydrochloride
azimilide
furanyl
Prior art date
Application number
MX2009006475A
Other languages
English (en)
Inventor
Nancy Lee Redman-Furey
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MX2009006475A publication Critical patent/MX2009006475A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida a solvatos y diversas formas polimórficas de d ¡clorhidrato de (E)-1 -[[[5-(4-clorofenil)-2- furanhl]metilen]amino]-3-[4-(4-metil-1 -piperazinil)butil]-2,4-imi dazoUdinadiona y composiciones farmacéuticas de éstas.
MX2009006475A 2006-12-15 2007-12-11 Composiciones de diclorhidrato de azimilida. MX2009006475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87505106P 2006-12-15 2006-12-15
PCT/IB2007/055037 WO2008072190A2 (en) 2006-12-15 2007-12-11 Compositions of azimilide dihydrochloride

Publications (1)

Publication Number Publication Date
MX2009006475A true MX2009006475A (es) 2009-06-26

Family

ID=39401118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006475A MX2009006475A (es) 2006-12-15 2007-12-11 Composiciones de diclorhidrato de azimilida.

Country Status (19)

Country Link
US (2) US20080182858A1 (es)
EP (1) EP2125791A2 (es)
JP (1) JP2010513264A (es)
KR (1) KR20090089416A (es)
CN (1) CN101558063A (es)
AR (1) AR064367A1 (es)
AU (1) AU2007331033A1 (es)
BR (1) BRPI0720265A2 (es)
CA (1) CA2672132A1 (es)
CL (1) CL2007003643A1 (es)
IL (1) IL198807A0 (es)
MA (1) MA30992B1 (es)
MX (1) MX2009006475A (es)
PE (1) PE20081481A1 (es)
RU (1) RU2009117558A (es)
SM (1) SMAP200900061A (es)
TW (1) TW200840578A (es)
WO (1) WO2008072190A2 (es)
ZA (1) ZA200903390B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016256776B2 (en) * 2009-03-18 2018-04-12 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2013248242B2 (en) * 2009-03-18 2016-08-18 Incarda Therapeutics, Inc Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CN101735203B (zh) * 2009-12-17 2012-05-23 天津药物研究院 盐酸阿齐利特的晶型ⅱ及其制备方法和用途
DK3380152T3 (da) * 2015-11-27 2021-02-01 Sanofi Aventis Deutschland Medikamentinjektionsanordning
SG11201805788WA (en) 2016-02-01 2018-08-30 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
CA3060702A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CN113861164B (zh) * 2021-10-29 2022-09-20 迪嘉药业集团有限公司 一种烟碱的结晶制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032645A (en) * 1975-06-19 1977-06-28 G. D. Searle & Co. Injectable metronidazole composition
EP1231208A3 (en) * 1991-08-14 2003-12-10 Procter & Gamble Pharmaceuticals 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents
NZ506773A (en) * 1998-04-29 2004-03-26 Procter & Gamble Process for making 1, 3-disubstituted-4-oxocyclic ureas
EP1075473B1 (en) * 1998-04-29 2007-07-04 The Procter & Gamble Company Process for making 1,3-disubstituted-4-oxocyclic ureas
DE602004024383D1 (de) * 2003-05-08 2010-01-14 Theravance Inc Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists

Also Published As

Publication number Publication date
CA2672132A1 (en) 2008-06-19
WO2008072190A2 (en) 2008-06-19
BRPI0720265A2 (pt) 2014-01-28
US20110237603A1 (en) 2011-09-29
US20080182858A1 (en) 2008-07-31
AR064367A1 (es) 2009-04-01
WO2008072190A3 (en) 2008-11-06
TW200840578A (en) 2008-10-16
CN101558063A (zh) 2009-10-14
PE20081481A1 (es) 2008-11-07
EP2125791A2 (en) 2009-12-02
RU2009117558A (ru) 2011-01-20
KR20090089416A (ko) 2009-08-21
AU2007331033A1 (en) 2008-06-19
CL2007003643A1 (es) 2008-03-24
ZA200903390B (en) 2010-04-28
MA30992B1 (fr) 2009-12-01
IL198807A0 (en) 2010-02-17
SMAP200900061A (it) 2009-09-07
JP2010513264A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
MX2009006475A (es) Composiciones de diclorhidrato de azimilida.
CL2007003459A1 (es) Proceso de preparacion de compuestos derivados de pirimidina; y compuesto intermediario (s)-trans-etil 3-etoxi-7-(4-(4-fluorofenil)-6-isopropil-2-(n-metilmetilsulfonamido)pirimidin-5-il)-5-hidroxihep-2,6-dienoato.
TNSN07196A1 (en) Potentiators of glutamate receptors
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
SG154433A1 (en) Phthalazine derivatives as parp inhibitors
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
EP1954683A4 (en) 2- (PHENYL OR HETEROCYCLYL) -1H-PHENANTHRO (9,10-D) IMIDAZOLE AS MPGES-1 INHIBITORS
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
ATE477252T1 (de) Substituierte diazepane als antagonisten an orexinrezeptoren
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
MY169515A (en) Quinazolinedione derivatives as parp inhibitors
UA92349C2 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
WO2008107478A8 (en) Quinolinone derivatives as parp and tank inhibitors
WO2007062399A3 (en) Oncogenic ras-specific cytotoxic compound and methods of use thereof
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
WO2009024823A8 (en) Cyclopropyl amide derivatives
BRPI0815048A2 (pt) derivado de fenóxi-pirrolidinas e uso e composições do mesmo
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
WO2006099268A3 (en) Cgrp receptor antagonists
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
EA201070691A1 (ru) Амидные соединения в качестве активаторов противовирусных препаратов
WO2007081995A3 (en) Urotensin ii receptor antagonists

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: WARNER CHILCOTT COMPANY, LLC

FA Abandonment or withdrawal